Intercure Ltd.
No SEC Form 4 filings for $INCR in the last 30 days.
See all $INCR insider activity →InterCure Ltd. (INCR) announced a 1-for-5 reverse share split to meet Nasdaq's $1.00 minimum price requirement. The split, approved by shareholders, reduces outstanding shares from 59.2M to 11.8M, effective August 24, 2026. INCR is trading at $0.92, down 3.13%. The company aims to comply with Nasdaq's rules and avoid delisting.
InterCure Ltd. (Nasdaq: INCR) said it completed the first tranche (50%) of its Botanico Ltd. (ISHI) acquisition, issuing 2,471,061 ordinary shares now and 2,470,073 later after conditions are met. The company launched a strategic review of regulated U.S. medical cannabis after federal rescheduling to Schedule III, and cited growing German demand and planned product launches in H2.
The Company reports NIS 130 million in revenue and NIS 12 million in positive operating cash flow, demonstrating resilience and sustained profitability with its eleventh consecutive half of positive Adjusted EBITDA amidst ongoing recovery in Israel
Over the past 7 days, alphai's AI scored 1 news story mentioning INCR (Intercure Ltd.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent INCR coverage spans financial news, corporate actions and mergers & acquisitions.
The reverse split will reduce share count and raise per‑share price, potentially stabilizing the stock above the Nasdaq minimum.
Deal progress plus a U.S. regulatory catalyst increases perceived growth optionality, but near-term execution/integration risk remains.
InterCure reported strong first-half 2025 financial results with NIS 130 million revenue and positive operating cash flow, marking its eleventh consecutive half of positive Adjusted EBITDA amidst ongoing recovery in Israel.
InterCure's acquisition of Botanico Ltd. (ISHI) signals a strategic move to strengthen its position in the premium US cannabis market, potentially leading to positive stock performance.
InterCure's acquisition of ISHI signifies a strategic move to expand into the U.S. cannabis market, potentially enhancing its product portfolio and technological capabilities.
alphai scores every news story that mentions INCR with an AI model for sentiment and relevance, and aggregates insider trades from Intercure Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
InterCure Ltd. (INCR) announced a 1-for-5 reverse share split to meet Nasdaq's $1.00 minimum price requirement. The split, approved by shareholders, reduces outstanding shares from 59.2M to 11.8M, effective August 24, 2026. INCR is trading at $0.92, down 3.13%. The company aims to comply with Nasdaq's rules and avoid delisting.
2 min readInterCure Ltd. (Nasdaq: INCR) said it completed the first tranche (50%) of its Botanico Ltd. (ISHI) acquisition, issuing 2,471,061 ordinary shares now and 2,470,073 later after conditions are met. The company launched a strategic review of regulated U.S. medical cannabis after federal rescheduling to Schedule III, and cited growing German demand and planned product launches in H2.
4 min readThe Company reports NIS 130 million in revenue and NIS 12 million in positive operating cash flow, demonstrating resilience and sustained profitability with its eleventh consecutive half of positive Adjusted EBITDA amidst ongoing recovery in Israel
2 min readInterCure Ltd. INCR revealed on Friday that it will acquire Botanico Ltd., known as ISHI, in a move designed to strengthen its global cannabis portfolio and deliver entry into premium American cultivation technology and brand partnerships.
3 min readAcquisition of leading cannabis company marks major milestone in InterCure's commercial expansion strategy, bringing access to premium American brands and state-of-the-art cultivation technologies
3 min read
